 "Jubilant Life Sciences")
Jubliant Life Sciences has rallied 9% to Rs 420, also its record high on the BSE, after the drug maker received nod from the US health regulator for its generic version of Merck's acute migraine treatment medicine, Maxalt-MLT.
The company on Tuesday, October 20, announced that it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally-disintegrating tablets, 5 mg and 10 mg.
The medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck, which is indicated for the acute treatment of migraine in adults and paediatric patients, it added.
Last week, on October 14, the company had received ANDA final approval from the USFDA for memantine hydrochloride tablets USP 5 mg and 10 mg, the generic version of Namenda of Forest Laboratories, which is used for treatment of moderate to severe dementia in patients with Alzheimer’s disease.
In past three months, the stock has appreciated more than 100% from Rs 198 on July 21, as compared to 3% decline in the Sensex.
At 03:00 pm, the stock was up 7% at Rs 416 on the BSE. The trading volumes on the counter more than doubled with a combined 3.47 million shares changed hands on the BSE and NSE so far.
The company on Tuesday, October 20, announced that it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally-disintegrating tablets, 5 mg and 10 mg.
The medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck, which is indicated for the acute treatment of migraine in adults and paediatric patients, it added.
Last week, on October 14, the company had received ANDA final approval from the USFDA for memantine hydrochloride tablets USP 5 mg and 10 mg, the generic version of Namenda of Forest Laboratories, which is used for treatment of moderate to severe dementia in patients with Alzheimer’s disease.
In past three months, the stock has appreciated more than 100% from Rs 198 on July 21, as compared to 3% decline in the Sensex.
At 03:00 pm, the stock was up 7% at Rs 416 on the BSE. The trading volumes on the counter more than doubled with a combined 3.47 million shares changed hands on the BSE and NSE so far.
